Two Strikes For Ketek: Cmtes. Want Bronchitis, Sinusitis Indications Rescinded
Executive Summary
FDA's Anti-Infective Drug and Drug Safety and Risk Management Advisory Committees are recommending stripping Sanofi-Aventis' Ketek of its bronchitis and sinusitis indications
You may also be interested in...
Antibiotics For ABS Should Have “Time To Symptom Relief” Trials, FDA Says
During clinical trials of antibiotics for treating acute bacterial sinusitis, "time to clinical success" is the recommended primary efficacy endpoint, FDA says in new draft guidance on developing ABS drugs
Antibiotics For ABS Should Have “Time To Symptom Relief” Trials, FDA Says
During clinical trials of antibiotics for treating acute bacterial sinusitis, "time to clinical success" is the recommended primary efficacy endpoint, FDA says in new draft guidance on developing ABS drugs
Antibiotic Efficacy Rereview Would Be Triggered Only By Safety Issues – FDA
Absent safety concerns, FDA is not planning to seek superiority trials for currently-marketed antibiotics, despite advisory committee concerns about the approval standards used for Sanofi-Aventis' Ketek (telithromycin)